Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Large B-Cell, Diffuse

Explore clinical trials studying Lymphoma, Large B-Cell, Diffuse. Study availability and eligibility vary by location and protocol.

1,249 public trials 217 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Large B-Cell, Diffuse trial results

Completed

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

NCT03484702

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Local Institution - 101 Vienna, Austria
  • Local Institution - 351 Ghent, Belgium
  • Local Institution - 551 Helsinki, Finland
  • Local Institution - 202 Lille, France
View all 20 locations
View Trial Details
Completed

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

NCT00243087

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +25 more
Locations
  • Lombardi Comprehensive Cancer Center at Georgetown University Medical Center Washington D.C., District of Columbia, United States
  • UNMC Eppley Cancer Center at the University of Nebraska Medical Center Omaha, Nebraska, United States
  • James P. Wilmot Cancer Center at University of Rochester Medical Center Rochester, New York, United States
  • M. D. Anderson Cancer Center at University of Texas Houston, Texas, United States
View Trial Details
Completed

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

NCT02112526

Conditions
Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL), Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Research Site Los Angeles, California, United States
  • Research Site Atlanta, Georgia, United States
  • Research Site New York, United States
  • Research Site Columbus, Ohio, United States
View Trial Details
Completed

Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL

NCT05233033

Conditions
DLBCL, Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, +12 more
Locations
  • MedStar Georgetown University Hospital Washington D.C., District of Columbia, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • Henry Ford Health System Detroit, Michigan, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details
Completed

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

NCT02924402

Conditions
B-Cell Non-Hodgkins Lymphoma, Blood Protein Disorders, Burkitt Lymphoma, +50 more
Locations
  • Moores UC San Diego Cancer Center La Jolla, California, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • Northside Hospital Atlanta, Georgia, United States
  • The University of Chicago Medicine Chicago, Illinois, United States
View all 23 locations
View Trial Details
Completed

Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

NCT03955783

Conditions
Acute Myeloid Leukemia, Diffuse Large B-cell Lymphoma, Hematologic Diseases, +15 more
Locations
  • Roswell Park Cancer Center Buffalo, New York, United States
  • University Hospitals of Cleveland Cleveland, Ohio, United States
  • Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States
  • University of Texas Southwestern Medical Center Dallas, Texas, United States
View Trial Details
Completed

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

NCT03520920

Conditions
Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Hemic and Lymphatic Diseases, +13 more
Locations
  • Harbin Medical University Cancer Hospital Harbin, Heilongjiang, China
  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology Wuhan, Hubei, China
  • The Affiliated Hospital of Xuzhou Medical University Xuzhou, Jiangsu, China
  • Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai Municipality, China
View Trial Details
Completed

Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

NCT03145064

Conditions
Diffuse Large B-cell Lymphoma, Disease Attributes, Hemic and Lymphatic Diseases, +13 more
Locations
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Harbin Medical University Cancer Hospital Harbin, Heilongjiang, China
  • Henan Cancer Hospital Zhengzhou, Henan, China
  • The First Affiliated Hospital of Soochow University Branch Shizi Suzhou, Jiangsu, China
View Trial Details

Related conditions